These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 27180793)

  • 41. [A complete response following treatment with Paclitaxel and bevacizumab for metastatic breast cancer].
    Tsubota Y; Sueoka N; Yamamoto D
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):1954-6. PubMed ID: 25731387
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre.
    Cheung KL; Owers R; Robertson JF
    Endocr Relat Cancer; 2006 Mar; 13(1):251-5. PubMed ID: 16601292
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [A case of estrogen receptor-positive metastatic breast cancer in a postmenopausal woman treated with ethinyl estradiol].
    Goto H; Inao T; Nakano M; Ibusuki M; Murakami K; Yamamoto Y; Iwase T
    Gan To Kagaku Ryoho; 2013 Dec; 40(13):2569-71. PubMed ID: 24335372
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [A Case of Triple Negative Breast Cancer with Successful Control of Recurrent Disease Activity for More than Ten Years].
    Yabe N; Watanuki R; Harada Y; Kondo A; Yanagisawa T; Maeda H; Kishi M; Yoshikawa T; Osumi K; Kamiya N; Sotome K; Ishii Y; Jinno H; Ikeda T; Watanabe M
    Gan To Kagaku Ryoho; 2023 Dec; 50(13):1759-1761. PubMed ID: 38303198
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lapatinib plus capecitabine resolved human epidermal growth factor receptor 2-positive brain metastases.
    Glück S; Castrellon A
    Am J Ther; 2009; 16(6):585-90. PubMed ID: 19287304
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Successful Treatment of Estrogen Receptor Positive, HER2 Negative Breast Cancer with Life-Threatening Multiple Bone Metastases Using the Combination of Fulvestrant and Palbociclib-A Case Report].
    Nakamura A; Shigekawa T; Asakawa H; Park K; Baba N
    Gan To Kagaku Ryoho; 2021 Oct; 48(10):1251-1254. PubMed ID: 34657057
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant.
    Robertson JF; Howell A; Gorbunova VA; Watanabe T; Pienkowski T; Lichinitser MR
    Breast Cancer Res Treat; 2005 Jul; 92(2):169-74. PubMed ID: 15986127
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [A case of metastatic breast carcinoma of the cervical muscles].
    Noda S; Kashiwagi S; Kawajiri H; Takashima T; Onoda N; Hirakawa K
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):2405-7. PubMed ID: 24394127
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Grade 4 epistaxis in a woman with metastatic breast cancer treated with bevacizumab: a case report.
    Yanagihara K; Takei H; Iida S; Yamashita K; Kurita T; Iwamoto M; Saegusa H; Uchida E
    J Nippon Med Sch; 2014; 81(5):333-6. PubMed ID: 25391703
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials.
    Vergote I; Robertson JF
    Br J Cancer; 2004 Mar; 90 Suppl 1(Suppl 1):S11-4. PubMed ID: 15094759
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
    von Minckwitz G; Conrad B; Reimer T; Decker T; Eidtmann H; Eiermann W; Hackmann J; Möbus V; Marmé F; Potenberg J; Stickeler E; Simon E; Thomssen C; Huober J; Denkert C; Alfer J; Jackisch C; Nekljudova V; Burchardi N; Loibl S;
    Cancer; 2015 Oct; 121(20):3639-48. PubMed ID: 26111104
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial.
    Xu B; Jiang Z; Shao Z; Wang J; Feng J; Song S; Chen Z; Gu K; Yu S; Zhang Y; Wang C; Zhang F; Yang J
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):223-30. PubMed ID: 20938664
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer.
    Wu Z; Gabrielson A; Hwang JJ; Pishvaian MJ; Weiner LM; Zhuang T; Ley L; Marshall JL; He AR
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1309-14. PubMed ID: 26507197
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [A case of elderly metastatic breast cancer with a complete response to treatment with capecitabine and cyclophosphamide].
    Iida S; Furukawa K; Yokoyama T; Yanagihara K; Iwasaki R; Noguchi T; Tsuchiya S; Sugisaki Y; Naito Z; Tajiri T
    Gan To Kagaku Ryoho; 2007 Oct; 34(10):1697-700. PubMed ID: 17940394
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.
    Mlineritsch B; Psenak O; Mayer P; Moik M; Namberger K; Hauser-Kronberger C; Greil R
    Breast Cancer Res Treat; 2007 Nov; 106(1):105-12. PubMed ID: 17295045
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [A patient with advanced recurrent breast cancer who firmly resisted hair loss and was then treated by combination therapy with high-dose toremifene and capecitabine].
    Akahane T; Chiba T; Yano H; Hashimoto Y
    Gan To Kagaku Ryoho; 2007 Mar; 34(3):435-8. PubMed ID: 17353638
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [A case of triple negative recurrent breast cancer successfully treated with capecitabine+docetaxel combination chemotherapy].
    Hachisuka Y; Kamei Y; Umeoka T; Kimura M; Uomoto M; Hatano H; Johira H; Yunoki S; Kawata N; Watanabe R; Ohmori K; Miyata N
    Gan To Kagaku Ryoho; 2008 Mar; 35(3):475-8. PubMed ID: 18347398
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
    von Minckwitz G; Kümmel S; Vogel P; Hanusch C; Eidtmann H; Hilfrich J; Gerber B; Huober J; Costa SD; Jackisch C; Loibl S; Mehta K; Kaufmann M;
    J Natl Cancer Inst; 2008 Apr; 100(8):542-51. PubMed ID: 18398097
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Two Cases of Lung Metastasis from Breast Cancer Successfully Treated with Endocrine Therapy].
    Hasegawa K; Higashi Y; Kamiya A; Takatsuno Y; Kondo I; Kaneko J; Endo T; Maejima S
    Gan To Kagaku Ryoho; 2016 Nov; 43(12):2419-2421. PubMed ID: 28133341
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
    Pivot X; Manikhas A; Żurawski B; Chmielowska E; Karaszewska B; Allerton R; Chan S; Fabi A; Bidoli P; Gori S; Ciruelos E; Dank M; Hornyak L; Margolin S; Nusch A; Parikh R; Nagi F; DeSilvio M; Santillana S; Swaby RF; Semiglazov V
    J Clin Oncol; 2015 May; 33(14):1564-73. PubMed ID: 25605838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.